Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1964
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1970 2
1971 2
1972 1
1973 5
1974 1
1975 1
1976 1
1977 1
1978 1
1980 3
1982 1
1983 1
1984 1
1985 2
1986 2
1987 4
1988 4
1989 2
1990 5
1991 3
1992 1
1993 4
1994 4
1995 3
1996 4
1997 5
1998 5
1999 2
2000 6
2001 2
2002 4
2003 5
2004 9
2005 4
2006 2
2007 2
2008 1
2009 2
2010 7
2011 3
2012 7
2013 8
2014 4
2015 6
2016 6
2017 5
2018 6
2019 4
2020 6
2021 3
2022 7
2023 10
2024 10
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Hypertrophic cardiomyopathy: the future of treatment.
Tuohy CV, Kaul S, Song HK, Nazer B, Heitner SB. Tuohy CV, et al. Eur J Heart Fail. 2020 Feb;22(2):228-240. doi: 10.1002/ejhf.1715. Epub 2020 Jan 9. Eur J Heart Fail. 2020. PMID: 31919938 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance. It is the most common inherited monogenic cardiac conditi …
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventric
Hypertrophic cardiomyopathy.
Maron BJ, Maron MS. Maron BJ, et al. Lancet. 2013 Jan 19;381(9862):242-55. doi: 10.1016/S0140-6736(12)60397-3. Epub 2012 Aug 6. Lancet. 2013. PMID: 22874472 Review.
Clinical diagnosis is based on otherwise unexplained left-ventricular hypertrophy identified by echocardiography or cardiovascular MRI. While presenting with a heterogeneous clinical profile and complex pathophysiology, effective treatment strategies are available, …
Clinical diagnosis is based on otherwise unexplained left-ventricular hypertrophy identified by echocardiography or cardiovasc …
Hypertrophic Cardiomyopathy: Clinical Update.
Geske JB, Ommen SR, Gersh BJ. Geske JB, et al. JACC Heart Fail. 2018 May;6(5):364-375. doi: 10.1016/j.jchf.2018.02.010. Epub 2018 Apr 11. JACC Heart Fail. 2018. PMID: 29655825 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, manifesting as left ventricular hypertrophy in the absence of a secondary cause. The genetic underpinnings of HCM arise largely from mutations of sarcomeric proteins; however, the specifi …
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, manifesting as left ventricular hypertrophy in …
Hypertrophic obstructive cardiomyopathy.
Veselka J, Anavekar NS, Charron P. Veselka J, et al. Lancet. 2017 Mar 25;389(10075):1253-1267. doi: 10.1016/S0140-6736(16)31321-6. Epub 2016 Nov 30. Lancet. 2017. PMID: 27912983 Review.
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness 15 mm) that is not explained by abnormal loading conditions, and left ventricular obstruction greater than or equal to 30 mm Hg. ...Some patient …
Hypertrophic obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall thickness 15 mm) that …
Tetralogy of Fallot.
Bailliard F, Anderson RH. Bailliard F, et al. Orphanet J Rare Dis. 2009 Jan 13;4:2. doi: 10.1186/1750-1172-4-2. Orphanet J Rare Dis. 2009. PMID: 19144126 Free PMC article. Review.
Tetralogy of Fallot is a congenital cardiac malformation that consists of an interventricular communication, also known as a ventricular septal defect, obstruction of the right ventricular outflow tract, override of the ventricular septum by the aortic …
Tetralogy of Fallot is a congenital cardiac malformation that consists of an interventricular communication, also known as a ventricular
Obstruction in Hypertrophic Cardiomyopathy: Many Faces.
Abbasi M, Ong KC, Newman DB, Dearani JA, Schaff HV, Geske JB. Abbasi M, et al. J Am Soc Echocardiogr. 2024 Jun;37(6):613-625. doi: 10.1016/j.echo.2024.02.010. Epub 2024 Feb 28. J Am Soc Echocardiogr. 2024. PMID: 38428652 Review.
Hypertrophic cardiomyopathy (HCM), the most common inherited cardiomyopathy, exhibits left ventricular hypertrophy not secondary to other causes, with varied phenotypic expression. ...Doppler echocardiography allows monitoring of therapeutic responses, whether it be …
Hypertrophic cardiomyopathy (HCM), the most common inherited cardiomyopathy, exhibits left ventricular hypertrophy not seconda …
Obstructive hypertrophic cardiomyopathy: a review of new therapies.
Mehra N, Ali AH, Desai MY. Mehra N, et al. Future Cardiol. 2023 Oct;19(13):661-670. doi: 10.2217/fca-2023-0056. Epub 2023 Nov 7. Future Cardiol. 2023. PMID: 37933625 Review.
The hallmarks of HCM include dynamic left ventricular outflow tract obstruction, typically caused by asymmetric septal hypertrophy. ...Hypertrophic obstructive cardiomyopathy is a genetic condition that leads to increased heart muscle size. This increa …
The hallmarks of HCM include dynamic left ventricular outflow tract obstruction, typically caused by asymmetric septal hype
Hypertrophic Cardiomyopathy 2020.
Kogut J, Popjes ED. Kogut J, et al. Curr Cardiol Rep. 2020 Oct 6;22(11):154. doi: 10.1007/s11886-020-01381-3. Curr Cardiol Rep. 2020. PMID: 33025145 Review.
Several medical therapies have been shown to reduce symptoms and improve functional capacity, including several recent phase 2 clinical trials involving the novel myosin modulator mavacamten. In patients with refractory symptoms, septal reduction therapy or advanced therap …
Several medical therapies have been shown to reduce symptoms and improve functional capacity, including several recent phase 2 clinical tria …
Hypertrophic cardiomyopathy.
Elliott P, McKenna WJ. Elliott P, et al. Lancet. 2004 Jun 5;363(9424):1881-91. doi: 10.1016/S0140-6736(04)16358-7. Lancet. 2004. PMID: 15183628 Review.
Hypertrophic cardiomyopathy is a common genetically transmitted disease, defined clinically by the presence of unexplained left ventricular hypertrophy. The disease has a varied clinical course and outcome; many patients have little or no discernible cardiovascular …
Hypertrophic cardiomyopathy is a common genetically transmitted disease, defined clinically by the presence of unexplained left ventricul
Ventricular septal defect.
Penny DJ, Vick GW 3rd. Penny DJ, et al. Lancet. 2011 Mar 26;377(9771):1103-12. doi: 10.1016/S0140-6736(10)61339-6. Epub 2011 Feb 23. Lancet. 2011. PMID: 21349577 Review.
Ventricular septal defects account for up to 40% of all congenital cardiac malformations. ...Presentation, symptoms, natural history, and management of ventricular septal defects depend on size and anatomical associations of the anomaly, patient's age,
Ventricular septal defects account for up to 40% of all congenital cardiac malformations. ...Presentation, symptoms, natural h
183 results